

Index

- acetylcholine 23
- β 2-adrenergic receptor 170
- African American family, phenotype asthma in 19
- agretope 39
- airway hyperresponsiveness (AHR) 113
- airway nitric oxide (FENO) 126, 130
- airway nitric oxide concentration 126
- airway remodelling 98
- allergen 24, 39, 64, 118
- allergic asthma 113
- allergy 86
- alpha chain, of IgE receptor 116
- Ambrosia artemisifolia* 62
- anchored PCR 67
- anergy 56
- α ₁-antitrypsin (AAT) 171
- association of HLA 61
- association study with NOS1 128
- asthma 1, 19, 25, 31, 64, 85–89, 95, 113, 128, 137, 139–144, 146, 148, 149, 152, 154–157, 167
- asthma susceptibility 143
- atopic asthma 113
- atopic disorder 1
- atopic disorders, mode of inheritance 2
- atopy 31, 85–88

- B-cell 55
- BALB/c mice 69
- birch tree pollen 64
- bronchial hyperreactivity 23
- bronchial hyperresponsiveness (BHR) 31, 86, 89
- bronchoalveolar lavage (BAL) eosinophil 117

- candidate gene for asthma 25, 128
- case-control association study 129
- Caucasian family, phenotype asthma in 19
- CD28 56
- CD80 56
- chromosome 12 128
- chromosome 11q13 85, 86, 88, 89
- chromosome 5q31-q33 113
- chronic obstructive pulmonary disease (COPD) 101
- citrus red mite asthma 64
- class II gene of MHC 59
- complex allergens 39
- complex trait mapping 29
- complex traits, Mendelian principles in 4
- cyclosporin A (CsA) 99
- CysLT₁ receptor 138, 139, 141, 143, 144, 153, 154, 156
- CysLT₂ receptor 138, 139, 141, 143, 144, 154–156
- cytokine 55

- Der p-specific IgE responsiveness 41
- Dermatophagoides pteronyssinus* 39
- diesel exhaust particle (DEP) 38
- dinucleotide repeat 17
- disease modification 137–157
- DNA repeat 17

- DNA replication 17
- DQB1*05 64
- DRB1 gene 62
- DRB1*07 genotype 64
- dust-mite antigen (DMA) 119

- eczema 85, 87
- endothelial NOS (NOS3) 125
- environmental exposure 18, 24
- eosinophil, BAL 117
- eosinophil count 19
- eosinophilic inflammation 113
- epitope 39, 67
- exhaled NO, contribution of NOS1 131
- experimental allergic encephalitis (EAE) 68
- extended-haplotype 64

- family and twin studies 1
- FcεRIβ 44, 86–89
- FVB/N-TG5 mice 118

- gene-mapping studies 11
- genetic homogeneity, complex disorders 11
- genetic linkage, mapping of asthma 113
- genetic polymorphism 153, 156
- genetic restriction 57
- genome scan 17, 128
- genome screen 31
- genetic severity, asthma 167

- high-affinity IgE receptor (FcεRIβ), β subunit 44, 86–89
- helper CD4⁺ T-cell 55
- heritability 4
- heterozygosity 17
- Hispanic family, phenotype asthma in 19
- HLA-DP 60
- HLA-DQ 60
- HLA-DR 60
- HLA/TCR, interaction 72
- house dust mite, associated to HLA (HDM) 61
- human leukocyte antigen (HLA) 38, 58, 60

- Hutterites 19, 29, 31–33

- IgE 19, 23, 37, 41, 87, 116, 117
- IgE antibody, specific 37
- IgE receptor 44, 86–89, 116
- IgE receptor, alpha chain 116
- IgE responsiveness, Der p-specific 37, 41
- IL-4 95, 169, 170
- IL-4 receptor 170
- IL-9 113, 114, 117, 120, 122
- IL-9 neutralizing antibody 120
- IL-9 receptor 113, 120
- IL-9-specific blockade 120
- IL-9 transgenic mice 117
- IL-13 95, 96
- IL-13 receptor 96
- immunoglobulin (Ig) 57
- immunologic synapse 66
- inducible NOS (NOS2) 125
- infection 24
- interaction of HLA/TCR 72
- isocyanate-induced asthma 64

- Leishmania major* 69
- leukotriene 139–141, 145, 146, 149, 151
- linkage disequilibrium of MHC 61
- linkage of HLA 61
- linkage study 128
- 5-lipoxygenase (LO) pathway 137, 138, 141–144, 149, 152

- major histocompatibility complex (MHC) 55, 57–59, 61
- mast cell 117
- mast cell chymase-1 71
- maternal inheritance 24
- MHC class I 58
- microsatellite 17
- mode of inheritance in atopic disorders 2
- modifier gene 168
- mouse model of asthma 126
- MUC2 117, 119

- MUC5AC 117, 119
mucosal Th2 immunity 113, 120
mucus production 96
- neuro-inflammatory interaction in asthma 133
neuronal NOS (NOS1) 125
neural control of airways 133
NF-AT 100, 102
nitric oxide (NO) 125
nitrosothiol (SNO) 126
NO synthase (NOS) 125, 128, 131
NOS1, association study 128
nonadrenergic noncholinergic (NANC)
 pathways 133
- oligoclonality of T cells 69
olive pollen allergen 64
ovalbumin 23
ovalbumin-induced airway hyperreactivity 68
- pan-allergen 64
phenotype asthma 19
polymerase chain reaction (PCR) 17, 67, 119
peak flow variation 23
peroxynitrite (OONO⁻) 126
pharmacogenetics 137, 142, 155
platelet-activating factor (PAF) 172
pleiotropy 24
polymorphism 25, 57, 66, 86–88, 98, 99, 105,
 131
polymorphism of MHC and TCR 57
polymorphisms in NOS1 131
positional cloning 18
probability, linkage 18
pulsed field gel electrophoresis (PFGE) 25
- quantitative trait locus (QTL) 115
- ragweed 62
recombination 18
rhinitis 85
rIL-9 117
- RT-PCR 119
- self-tolerance 57
serum total IgE 117
severity 24, 167
single-nucleotide polymorphism (SNP) 25
skin prick test 19
somatic rearrangement of TCR 65
specific IgE responsiveness 37
specific immunoglobulin E (IgE) antibody 37
STAT-6 97
super-antigen 70
susceptibility alleles 11
- T cell 43, 55–57, 65, 66, 69, 71, 72, 99
T cell, activation 56
T cell, oligoclonality 69
T cell, repertoire 66
T-cell receptor (TCR) 43, 55, 57, 65, 66, 69,
 71, 72
TCR $\alpha\beta$ 65
TCR $\gamma\delta$ 65
TCR A/D locus 71
TCR AV gene 72
TCR diversity 65
TCR haplotype 66
Th2 cell 55
Th2 cytokine 95
Th2 mucosal immunity 113, 120
TNF α 172
total IgE level 87
trinucleotide repeats in neurodegenerative
 diseases 132
Tristan da Cunha 19
- V β of TCR 69
- western red cedar 64
- XY pseudo-autosomal region 120
- yeast artificial chromosome (YAC) 25

The PIR-Series

Progress in Inflammation Research

Homepage: <http://www.birkhauser.ch>

Up-to-date information on the latest developments in the pathology, mechanisms and therapy of inflammatory disease are provided in this monograph series. Areas covered include vascular responses, skin inflammation, pain, neuroinflammation, arthritis cartilage and bone, airways inflammation and asthma, allergy, cytokines and inflammatory mediators, cell signalling, and recent advances in drug therapy. Each volume is edited by acknowledged experts providing succinct overviews on specific topics intended to inform and explain. The series is of interest to academic and industrial biomedical researchers, drug development personnel and rheumatologists, allergists, pathologists, dermatologists and other clinicians requiring regular scientific updates.

Available volumes:

- T Cells in Arthritis*, P. Miossec, W. van den Berg, G. Firestein (Editors), 1998
Chemokines and Skin, E. Kownatzki, J. Norgauer (Editors), 1998
Medicinal Fatty Acids, J. Kremer (Editor), 1998
Inducible Enzymes in the Inflammatory Response, D.A. Willoughby, A. Tomlinson (Editors), 1999
Cytokines in Severe Sepsis and Septic Shock, H. Redl, G. Schlag (Editors), 1999
Fatty Acids and Inflammatory Skin Diseases, J.-M. Schröder (Editor), 1999
Immunomodulatory Agents from Plants, H. Wagner (Editor), 1999
Cytokines and Pain, L. Watkins, S. Maier (Editors), 1999
In Vivo Models of Inflammation, D. Morgan, L. Marshall (Editors), 1999
Pain and Neurogenic Inflammation, S.D. Brain, P. Moore (Editors), 1999
Anti-Inflammatory Drugs in Asthma, A.P. Sampson, M.K. Church (Editors), 1999
Novel Inhibitors of Leukotrienes, G. Folco, B. Samuelsson, R.C. Murphy (Editors), 1999
Vascular Adhesion Molecules and Inflammation, J.D. Pearson (Editor), 1999
Metalloproteinases as Targets for Anti-Inflammatory Drugs, K.M.K. Bottomley, D. Bradshaw, J.S. Nixon (Editors), 1999
Free Radicals and Inflammation, P.G. Winyard, D.R. Blake, C.H. Evans (Editors), 1999
Gene Therapy in Inflammatory Diseases, C.H. Evans, P. Robbins (Editors), 2000
New Cytokines as Potential Drugs, S. K. Narula, R. Coffmann (Editors), 2000
High Throughput Screening for Novel Anti-inflammatories, M. Kahn (Editor), 2000
Immunology and Drug Therapy of Atopic Skin Diseases, C.A.F. Bruijnzeel-Komen, E.F. Knol (Editors), 2000
Novel Cytokine Inhibitors, G.A. Higgs, B. Henderson (Editors), 2000
Inflammatory Processes. Molecular Mechanisms and Therapeutic Opportunities, L.G. Letts, D.W. Morgan (Editors), 2000

- Cellular Mechanisms in Airways Inflammation*, C. Page, K. Banner, D. Spina (Editors), 2000
- Inflammatory and Infectious Basis of Atherosclerosis*, J.L. Mehta (Editor), 2001
- Muscarinic Receptors in Airways Diseases*, J. Zaagsma, H. Meurs, A.F. Roffel (Editors), 2001
- TGF- β and Related Cytokines in Inflammation*, S.N. Breit, S. Wahl (Editors), 2001
- Nitric Oxide and Inflammation*, D. Salvemini, T.R. Billiar, Y. Vodovotz (Editors), 2001
- Neuroinflammatory Mechanisms in Alzheimer's Disease. Basic and Clinical Research*, J. Rogers (Editor), 2001
- Disease-modifying Therapy in Vasculitides*, C.G.M. Kallenberg, J.W. Cohen Tervaert (Editors), 2001
- Inflammation and Stroke*, G.Z. Feuerstein (Editor), 2001
- NMDA Antagonists as Potential Analgesic Drugs*, D.J.S. Sirinathsinghji, R.G. Hill (Editors), 2002
- Migraine: A Neuroinflammatory Disease?* E.L.H. Spierings, M. Sanchez del Rio (Editors), 2002
- Mechanisms and Mediators of Neuropathic Pain*, A.B. Malmberg, S.R. Chaplan (Editors), 2002
- Bone Morphogenetic Proteins: From Laboratory to Clinical Practice*, S. Vukicevic, K.T. Sampath (Editors), 2002